2016 American Society of Hematology Annual Meeting*

December 3-6, 2016; San Diego, California
Shaji Kumar, MD, and Sagar Lonial, MD, review data from key myeloma presentations at the 2016 American Society of Hematology Annual Meeting.
Shaji Kumar, MD
Sagar Lonial, MD

Myeloma and Plasma Cell Disorders

KRd for 8 cycles of induction and consolidation therapy in patients with MM was highly effective but resulted in some cardiovascular adverse events.

Released: December 9, 2016

Weekly carfilzomib with pomalidomide and low-dose dexamethasone appears effective with better tolerability in relapsed/refractory MM.

Released: December 7, 2016

This open-label, multicenter, dose-finding phase Ib trial suggests that subcutaneous daratumumab plus rHuPH20 is safe and effective in patients with relapsed/refractory MM.

Released: December 7, 2016

Response-adapted use of sequential IMiD- and PI-based induction therapy improves response depth and PFS in newly diagnosed multiple myeloma.

Released: December 6, 2016

Addition of daratumumab to either Rd or Vd significantly increased MRD-negative responses even in high-risk patients with relapsed/refractory multiple myeloma.

Released: December 5, 2016

Venetoclax was safe and tolerable in heavily pretreated patients with myeloma with an ORR of 40% in patients with t(11;14) translocation.

Released: December 7, 2016

Combination treatment with pembrolizumab plus pomalidomide/dexamethasone showed an ORR of 65% in relapsed/refractory MM.

Released: December 8, 2016

First-in-class XPO1 inhibitor selinexor, in combination with low-dose dexamethasone, shows encouraging activity in heavily pretreated patients with MM refractory to multiple immunomodulatory agents, proteasome inhibitors, and anti-CD-38 monoclonal antibodies, according to the phase II STORM trial data.

Released: December 6, 2016

Combination daratumumab/pomalidomide/dexamethasone produced deep responses and long PFS in patients with R/R MM, including those refractory to IMiDs and proteasome inhibitors.

Released: December 12, 2016

In this Expert Analysis, Sagar Lonial, MD, and Shaji Kumar, MD, discuss the clinical applicability of new, key findings in multiple myeloma presented at Hematology 2016.

Shaji Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 1, 2017 Expired: No longer available for credit

After current standard-of-care induction therapy for newly diagnosed MM, similar survival outcomes seen with single ASCT and maintenance lenalidomide with or without additional RVD consolidation or tandem ASCT even in patients with high-risk disease.

Released: December 9, 2016

In this downloadable slideset, Shaji Kumar, MD, and Sagar Lonial, MD, highlight the key data presented at Hematology 2016.

Released: December 27, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue